Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter

Q2 2024 operating income of $2.4 millionQ2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 millionQ2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted EBITDA of $5.5 millionQ2 2024 ADHD Portfolio net revenue up 49% compared to Q2 2023$19.5 million cash balance at Decem...

Related Keywords

United States ,Denver ,Colorado ,Roger Weiss ,Josh Disbrow ,Mark Oki ,Aytu Rxconnect ,Consumer Health Segment ,Company Consumer Health Segment ,Consumer Health ,Aytu Biopharma Inc ,Securities Exchange ,Company Rx Segment ,Exchange Commission ,Company Or Aytu ,Aytu Biopharma ,Health Segment ,Chief Executive Officer ,Pediatric Portfolio ,Pediatrics Portfolio ,Full Prescribing Information ,Securities Act ,Securities Exchange Act ,Annual Report ,Chief Financial ,Consolidated Statements ,Net Income ,Three Months Ended December ,